Biotest AG: Annual General Meeting: Shareholders Approve Dividend of EUR 0,30 per Ordinary Share and EUR 0,36 per Preference Share
Biotest AG / AGM/EGM
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Annual General Meeting: Shareholders Approve Dividend of EUR 0,30 per
Ordinary Share and EUR 0,36 per Preference Share
Dreieich/ Frankfurt am Main, May 7, 2009 - Shareholders of Biotest AG with
79,11% of shareholder present, approved a dividend of EUR 0.30 per
ordinary share for 2008 and a dividend of EUR 0.36 per preference share at
the company's Annual General Meeting held today in Frankfurt/ Main. This
corresponds to a total dividend payout of about EUR 3.8 million.
The Annual General Meeting approved by a large majority (97% of the present
voting stock) the creation of authorized capital stock, out of which
preference shares could have been issued to employees of the corporation
and its related companies.
At the subsequent meeting of preferred shareholders, however, with 45,98%
of shareholders present, the agenda item failed to achieve the required
three-quarters majority. Consequently, it is not possible to implement the
employee participation program as scheduled.
In addition, the Annual General Meeting approved the ratification of the
acts of management of the members of the Management Board and of the
members of the Supervisory Board for 2008 and approved all other proposals
put forward by the Management Board and Supervisory Board.
About 140 shareholders and guests took part in the Annual General Meeting.
The Annual General Meeting approved Prof. Dr. Marbod Muff as member of the
Supervisory Board by election.
The Supervisory Board consists of the following members:
Dr. Thorlef Spickschen (Chairman), Dr. Cathrin Schleussner (Deputy
Chairwoman),
Barbara Arnold-Schlosser*, Thomas Jakob, Prof. Dr. Marbod Muff,
Astrid Paluch* (*employee representative)
The full version of Prof. Dr. Gregor Schulz's speech is online available
at:
www.biotest.de/ Investor Relations/ AGM
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a company that researches and manufactures pharmaceutical,
biotherapeutic and diagnostic products and has specialised in the areas of
application of immunology and haematology. In its Plasma Protein segment,
Biotest develops and markets immunoglobulins, coagulation factors and
albumins based on human blood plasma. These are used for diseases of the
immune and haematopoietic systems. In the Biotherapeutic segment, Biotest
researches into the clinical development of monoclonal antibodies,
including in the indications of rheumatoid arthritis and cancer of plasma
cells. The products of the Microbiological Monitoring segment are primarily
used in hygiene monitoring, while those of Medical Diagnostics are used,
for example, in blood transfusions and transplants. Biotest has around
2,000 employees worldwide. The shares of Biotest AG are listed in the SDAX
on the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/Official traded Frankfurt, Berlin, Düsseldorf,
Hamburg, Stuttgart
07.05.2009 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
